Market-Moving News for March 19th
Market-Moving News for March 19th
CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs
CERS：64% | Cerus Corporation宣佈其INTERCEPT血液系統的Recepi三期試驗已達到其主要療效終點；截取紅細胞在上次輸血後28天內出現任何相關治療-緊急不良事件的患者比例的安全終點沒有顯著差異
CRNX: 20% | Crinetics Pharmaceuticals shares are trading higher after the company's Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly achieved the primary and all secondary endpoints.
CRNX：20% | Crinetics Pharmaceuticals的Paltusotine治療肢端肥大症的3期 PATHFNDR-2 試驗達到了主要終點和所有次要終點後，該公司的股價走高。
HOTH: 60% | Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer's Disease.
HOTH：60% | Hoth Therapeutics表示，HT-ALZ已成爲對抗與阿爾茨海默氏病相關的神經炎症和認知缺陷的有前途的新型解決方案。